A5089300031- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Microscopic Colitis
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal motility and disorders
- Nosocomial Infections in ICU
Aarhus University Hospital
2024-2025
Aarhus University
2024-2025
Faecal microbiota transplantation (FMT) is an effective treatment for patients with recurrent Clostridioides difficile infection, but donor selection can influence its clinical success. We aimed to investigate the effect of characteristics on FMT outcomes in C infection. In this single-centre, prospective cohort study, we included all donors who fulfilled national criteria faeces donation and delivered donations Centre Microbiota Transplantation, Aarhus University Hospital, Denmark, between...
Background & AimsClostridioides difficile infection (CDI) is associated with high mortality. Fecal microbiota transplantation (FMT) an established treatment for recurrent CDI, but its use first or second CDI remains experimental. We aimed to investigate the effectiveness of FMT in a real-world clinical setting.MethodsThis multi-site Danish cohort study included patients treated from June 2019 February 2023. The primary outcome was cure C. difficile-associated diarrhea (CDAD) 8 weeks after...
Faecal microbiota transplantation (FMT) is a highly effective treatment for
For Clostridioides difficile infection (CDI), faecal microbiota transplantation (FMT) is currently recommended for patients with three or more CDI episodes. A recent randomised controlled trial (RCT) show that FMT may be considered early, defined as intervention during the first second episode. Compared standard care CDI, to had €1,645 lower hospital costs over 26 weeks owing fewer admissions and contacts less medication use.